Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH and Fibrotic Diseases

Shots:

• Pliant to receive $80M including upfront & equity investment and eligible to receive development, regulatory and commercial milestones with royalties on sales. Novartis to get exclusive WW license for Pliant’s PLN-1474 and up to three additional candidates
• Novartis will be responsible for all future development, manufacturing and commercial activities, a post-P-I study of PLN-1474, prior to which Pliant will be responsible for all activities
• PLN-1474 is a pre-clinical candidate that selectively inhibit integrin αVβ1, currently being developed for the treatment of liver fibrosis associated with NASH with its expected IND submission to the US FDA by the year-end 2019

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Straitstimes